Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Antibody CDMO
1.2.3 Recombinant Protein CDMO
1.3 Market by Application
1.3.1 Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Generic Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody and Recombinant Protein CDMO Market Perspective (2018-2033)
2.2 Global Antibody and Recombinant Protein CDMO Growth Trends by Region
2.2.1 Antibody and Recombinant Protein CDMO Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Antibody and Recombinant Protein CDMO Historic Market Size by Region (2018-2023)
2.2.3 Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2024-2033)
2.3 Antibody and Recombinant Protein CDMO Market Dynamics
2.3.1 Antibody and Recombinant Protein CDMO Industry Trends
2.3.2 Antibody and Recombinant Protein CDMO Market Drivers
2.3.3 Antibody and Recombinant Protein CDMO Market Challenges
2.3.4 Antibody and Recombinant Protein CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Antibody and Recombinant Protein CDMO by Players
3.1.1 Global Antibody and Recombinant Protein CDMO Revenue by Players (2018-2023)
3.1.2 Global Antibody and Recombinant Protein CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Antibody and Recombinant Protein CDMO, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio
3.4.1 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody and Recombinant Protein CDMO Revenue in 2022
3.5 Global Key Players of Antibody and Recombinant Protein CDMO Head office and Area Served
3.6 Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application
3.7 Global Key Players of Antibody and Recombinant Protein CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody and Recombinant Protein CDMO Breakdown Data by Type
4.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Type (2018-2023)
4.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2024-2033)
5 Antibody and Recombinant Protein CDMO Breakdown Data by Application
5.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Application (2018-2023)
5.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Antibody and Recombinant Protein CDMO Market Size (2018-2033)
6.2 North America Antibody and Recombinant Protein CDMO Market Size by Type
6.2.1 North America Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023)
6.2.2 North America Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033)
6.2.3 North America Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
6.3 North America Antibody and Recombinant Protein CDMO Market Size by Application
6.3.1 North America Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023)
6.3.2 North America Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033)
6.3.3 North America Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
6.4 North America Antibody and Recombinant Protein CDMO Market Size by Country
6.4.1 North America Antibody and Recombinant Protein CDMO Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Antibody and Recombinant Protein CDMO Market Size by Country (2018-2023)
6.4.3 North America Antibody and Recombinant Protein CDMO Market Size by Country (2024-2033)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Antibody and Recombinant Protein CDMO Market Size (2018-2033)
7.2 Europe Antibody and Recombinant Protein CDMO Market Size by Type
7.2.1 Europe Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023)
7.2.2 Europe Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033)
7.2.3 Europe Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Application
7.3.1 Europe Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023)
7.3.2 Europe Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033)
7.3.3 Europe Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
7.4 Europe Antibody and Recombinant Protein CDMO Market Size by Country
7.4.1 Europe Antibody and Recombinant Protein CDMO Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2018-2023)
7.4.3 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Antibody and Recombinant Protein CDMO Market Size (2018-2033)
8.2 China Antibody and Recombinant Protein CDMO Market Size by Type
8.2.1 China Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023)
8.2.2 China Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033)
8.2.3 China Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
8.3 China Antibody and Recombinant Protein CDMO Market Size by Application
8.3.1 China Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023)
8.3.2 China Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033)
8.3.3 China Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Antibody and Recombinant Protein CDMO Market Size (2018-2033)
9.2 Asia Antibody and Recombinant Protein CDMO Market Size by Type
9.2.1 Asia Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023)
9.2.2 Asia Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033)
9.2.3 Asia Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
9.3 Asia Antibody and Recombinant Protein CDMO Market Size by Application
9.3.1 Asia Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023)
9.3.2 Asia Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033)
9.3.3 Asia Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
9.4 Asia Antibody and Recombinant Protein CDMO Market Size by Region
9.4.1 Asia Antibody and Recombinant Protein CDMO Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Antibody and Recombinant Protein CDMO Market Size by Region (2018-2023)
9.4.3 Asia Antibody and Recombinant Protein CDMO Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type
10.2.1 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application
10.3.1 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country
10.4.1 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Batavia Biosciences
11.1.1 Batavia Biosciences Company Details
11.1.2 Batavia Biosciences Business Overview
11.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Introduction
11.1.4 Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.1.5 Batavia Biosciences Recent Developments
11.2 Grifols
11.2.1 Grifols Company Details
11.2.2 Grifols Business Overview
11.2.3 Grifols Antibody and Recombinant Protein CDMO Introduction
11.2.4 Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.2.5 Grifols Recent Developments
11.3 Cerbios-Pharma SA
11.3.1 Cerbios-Pharma SA Company Details
11.3.2 Cerbios-Pharma SA Business Overview
11.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Introduction
11.3.4 Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.3.5 Cerbios-Pharma SA Recent Developments
11.4 HALIX
11.4.1 HALIX Company Details
11.4.2 HALIX Business Overview
11.4.3 HALIX Antibody and Recombinant Protein CDMO Introduction
11.4.4 HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.4.5 HALIX Recent Developments
11.5 Biovian Oy
11.5.1 Biovian Oy Company Details
11.5.2 Biovian Oy Business Overview
11.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Introduction
11.5.4 Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.5.5 Biovian Oy Recent Developments
11.6 Catalent
11.6.1 Catalent Company Details
11.6.2 Catalent Business Overview
11.6.3 Catalent Antibody and Recombinant Protein CDMO Introduction
11.6.4 Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.6.5 Catalent Recent Developments
11.7 Goodwin Biotechnology
11.7.1 Goodwin Biotechnology Company Details
11.7.2 Goodwin Biotechnology Business Overview
11.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Introduction
11.7.4 Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.7.5 Goodwin Biotechnology Recent Developments
11.8 Merck
11.8.1 Merck Company Details
11.8.2 Merck Business Overview
11.8.3 Merck Antibody and Recombinant Protein CDMO Introduction
11.8.4 Merck Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.8.5 Merck Recent Developments
11.9 Hangzhou Hs-biopharm
11.9.1 Hangzhou Hs-biopharm Company Details
11.9.2 Hangzhou Hs-biopharm Business Overview
11.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Introduction
11.9.4 Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.9.5 Hangzhou Hs-biopharm Recent Developments
11.10 Wuxibiologics
11.10.1 Wuxibiologics Company Details
11.10.2 Wuxibiologics Business Overview
11.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Introduction
11.10.4 Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.10.5 Wuxibiologics Recent Developments
11.11 Bioinnobio
11.11.1 Bioinnobio Company Details
11.11.2 Bioinnobio Business Overview
11.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Introduction
11.11.4 Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.11.5 Bioinnobio Recent Developments
11.12 Thousand Oaks Biopharmaceuticals
11.12.1 Thousand Oaks Biopharmaceuticals Company Details
11.12.2 Thousand Oaks Biopharmaceuticals Business Overview
11.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Introduction
11.12.4 Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.12.5 Thousand Oaks Biopharmaceuticals Recent Developments
11.13 Eurogentec
11.13.1 Eurogentec Company Details
11.13.2 Eurogentec Business Overview
11.13.3 Eurogentec Antibody and Recombinant Protein CDMO Introduction
11.13.4 Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.13.5 Eurogentec Recent Developments
11.14 HJB
11.14.1 HJB Company Details
11.14.2 HJB Business Overview
11.14.3 HJB Antibody and Recombinant Protein CDMO Introduction
11.14.4 HJB Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.14.5 HJB Recent Developments
11.15 Bibo Pharma
11.15.1 Bibo Pharma Company Details
11.15.2 Bibo Pharma Business Overview
11.15.3 Bibo Pharma Antibody and Recombinant Protein CDMO Introduction
11.15.4 Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.15.5 Bibo Pharma Recent Developments
11.16 MabPlex International
11.16.1 MabPlex International Company Details
11.16.2 MabPlex International Business Overview
11.16.3 MabPlex International Antibody and Recombinant Protein CDMO Introduction
11.16.4 MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.16.5 MabPlex International Recent Developments
11.17 Genscriptprobio
11.17.1 Genscriptprobio Company Details
11.17.2 Genscriptprobio Business Overview
11.17.3 Genscriptprobio Antibody and Recombinant Protein CDMO Introduction
11.17.4 Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.17.5 Genscriptprobio Recent Developments
11.18 Vetter
11.18.1 Vetter Company Details
11.18.2 Vetter Business Overview
11.18.3 Vetter Antibody and Recombinant Protein CDMO Introduction
11.18.4 Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.18.5 Vetter Recent Developments
11.19 Etinpro (Beijing) Co
11.19.1 Etinpro (Beijing) Co Company Details
11.19.2 Etinpro (Beijing) Co Business Overview
11.19.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Introduction
11.19.4 Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.19.5 Etinpro (Beijing) Co Recent Developments
11.20 Boehringer Ingelheim BioXcellence
11.20.1 Boehringer Ingelheim BioXcellence Company Details
11.20.2 Boehringer Ingelheim BioXcellence Business Overview
11.20.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Introduction
11.20.4 Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.20.5 Boehringer Ingelheim BioXcellence Recent Developments
11.21 Lonza
11.21.1 Lonza Company Details
11.21.2 Lonza Business Overview
11.21.3 Lonza Antibody and Recombinant Protein CDMO Introduction
11.21.4 Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.21.5 Lonza Recent Developments
11.22 3SBio Inc
11.22.1 3SBio Inc Company Details
11.22.2 3SBio Inc Business Overview
11.22.3 3SBio Inc Antibody and Recombinant Protein CDMO Introduction
11.22.4 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.22.5 3SBio Inc Recent Developments
11.23 Porton
11.23.1 Porton Company Details
11.23.2 Porton Business Overview
11.23.3 Porton Antibody and Recombinant Protein CDMO Introduction
11.23.4 Porton Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023)
11.23.5 Porton Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Antibody CDMO
Table 3. Key Players of Recombinant Protein CDMO
Table 4. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 5. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Antibody and Recombinant Protein CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Antibody and Recombinant Protein CDMO Market Share by Region (2018-2023)
Table 8. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Antibody and Recombinant Protein CDMO Market Share by Region (2024-2033)
Table 10. Antibody and Recombinant Protein CDMO Market Trends
Table 11. Antibody and Recombinant Protein CDMO Market Drivers
Table 12. Antibody and Recombinant Protein CDMO Market Challenges
Table 13. Antibody and Recombinant Protein CDMO Market Restraints
Table 14. Global Antibody and Recombinant Protein CDMO Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Antibody and Recombinant Protein CDMO Revenue Share by Players (2018-2023)
Table 16. Global Top Antibody and Recombinant Protein CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2022)
Table 17. Global Antibody and Recombinant Protein CDMO Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Antibody and Recombinant Protein CDMO Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Antibody and Recombinant Protein CDMO, Headquarters and Area Served
Table 20. Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application
Table 21. Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2018-2023)
Table 25. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2024-2033)
Table 27. Global Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Antibody and Recombinant Protein CDMO Revenue Share by Application (2018-2023)
Table 29. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Antibody and Recombinant Protein CDMO Revenue Share by Application (2024-2033)
Table 31. North America Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 33. North America Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 35. North America Antibody and Recombinant Protein CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. North America Antibody and Recombinant Protein CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Antibody and Recombinant Protein CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 38. Europe Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 40. Europe Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 42. Europe Antibody and Recombinant Protein CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 45. China Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 47. China Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 49. Asia Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 51. Asia Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 53. Asia Antibody and Recombinant Protein CDMO Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 54. Asia Antibody and Recombinant Protein CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Antibody and Recombinant Protein CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 61. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 63. Batavia Biosciences Company Details
Table 64. Batavia Biosciences Business Overview
Table 65. Batavia Biosciences Antibody and Recombinant Protein CDMO Product
Table 66. Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 67. Batavia Biosciences Recent Developments
Table 68. Grifols Company Details
Table 69. Grifols Business Overview
Table 70. Grifols Antibody and Recombinant Protein CDMO Product
Table 71. Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 72. Grifols Recent Developments
Table 73. Cerbios-Pharma SA Company Details
Table 74. Cerbios-Pharma SA Business Overview
Table 75. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product
Table 76. Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 77. Cerbios-Pharma SA Recent Developments
Table 78. HALIX Company Details
Table 79. HALIX Business Overview
Table 80. HALIX Antibody and Recombinant Protein CDMO Product
Table 81. HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 82. HALIX Recent Developments
Table 83. Biovian Oy Company Details
Table 84. Biovian Oy Business Overview
Table 85. Biovian Oy Antibody and Recombinant Protein CDMO Product
Table 86. Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 87. Biovian Oy Recent Developments
Table 88. Catalent Company Details
Table 89. Catalent Business Overview
Table 90. Catalent Antibody and Recombinant Protein CDMO Product
Table 91. Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 92. Catalent Recent Developments
Table 93. Goodwin Biotechnology Company Details
Table 94. Goodwin Biotechnology Business Overview
Table 95. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product
Table 96. Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 97. Goodwin Biotechnology Recent Developments
Table 98. Merck Company Details
Table 99. Merck Business Overview
Table 100. Merck Antibody and Recombinant Protein CDMO Product
Table 101. Merck Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 102. Merck Recent Developments
Table 103. Hangzhou Hs-biopharm Company Details
Table 104. Hangzhou Hs-biopharm Business Overview
Table 105. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product
Table 106. Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 107. Hangzhou Hs-biopharm Recent Developments
Table 108. Wuxibiologics Company Details
Table 109. Wuxibiologics Business Overview
Table 110. Wuxibiologics Antibody and Recombinant Protein CDMO Product
Table 111. Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 112. Wuxibiologics Recent Developments
Table 113. Bioinnobio Company Details
Table 114. Bioinnobio Business Overview
Table 115. Bioinnobio Antibody and Recombinant Protein CDMO Product
Table 116. Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 117. Bioinnobio Recent Developments
Table 118. Thousand Oaks Biopharmaceuticals Company Details
Table 119. Thousand Oaks Biopharmaceuticals Business Overview
Table 120. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product
Table 121. Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 122. Thousand Oaks Biopharmaceuticals Recent Developments
Table 123. Eurogentec Company Details
Table 124. Eurogentec Business Overview
Table 125. Eurogentec Antibody and Recombinant Protein CDMO Product
Table 126. Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 127. Eurogentec Recent Developments
Table 128. HJB Company Details
Table 129. HJB Business Overview
Table 130. HJB Antibody and Recombinant Protein CDMO Product
Table 131. HJB Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 132. HJB Recent Developments
Table 133. Bibo Pharma Company Details
Table 134. Bibo Pharma Business Overview
Table 135. Bibo Pharma Antibody and Recombinant Protein CDMO Product
Table 136. Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 137. Bibo Pharma Recent Developments
Table 138. MabPlex International Company Details
Table 139. MabPlex International Business Overview
Table 140. MabPlex International Antibody and Recombinant Protein CDMO Product
Table 141. MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 142. MabPlex International Recent Developments
Table 143. Genscriptprobio Company Details
Table 144. Genscriptprobio Business Overview
Table 145. Genscriptprobio Antibody and Recombinant Protein CDMO Product
Table 146. Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 147. Genscriptprobio Recent Developments
Table 148. Vetter Company Details
Table 149. Vetter Business Overview
Table 150. Vetter Antibody and Recombinant Protein CDMO Product
Table 151. Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 152. Vetter Recent Developments
Table 153. Etinpro (Beijing) Co Company Details
Table 154. Etinpro (Beijing) Co Business Overview
Table 155. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product
Table 156. Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 157. Etinpro (Beijing) Co Recent Developments
Table 158. Boehringer Ingelheim BioXcellence Company Details
Table 159. Boehringer Ingelheim BioXcellence Business Overview
Table 160. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product
Table 161. Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 162. Boehringer Ingelheim BioXcellence Recent Developments
Table 163. Lonza Company Details
Table 164. Lonza Business Overview
Table 165. Lonza Antibody and Recombinant Protein CDMO Product
Table 166. Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 167. Lonza Recent Developments
Table 168. 3SBio Inc Company Details
Table 169. 3SBio Inc Business Overview
Table 170. 3SBio Inc Antibody and Recombinant Protein CDMO Product
Table 171. 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 172. 3SBio Inc Recent Developments
Table 173. Porton Company Details
Table 174. Porton Business Overview
Table 175. Porton Antibody and Recombinant Protein CDMO Product
Table 176. Porton Revenue in Antibody and Recombinant Protein CDMO Business (2018-2023) & (US$ Million)
Table 177. Porton Recent Developments
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Antibody and Recombinant Protein CDMO Market Share by Type: 2022 VS 2033
Figure 3. Antibody CDMO Features
Figure 4. Recombinant Protein CDMO Features
Figure 5. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 6. Global Antibody and Recombinant Protein CDMO Market Share by Application: 2022 VS 2033
Figure 7. Pharmaceutical Company Case Studies
Figure 8. Biotechnology Company Case Studies
Figure 9. Generic Company Case Studies
Figure 10. Antibody and Recombinant Protein CDMO Report Years Considered
Figure 11. Global Antibody and Recombinant Protein CDMO Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Antibody and Recombinant Protein CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Antibody and Recombinant Protein CDMO Market Share by Region: 2022 VS 2033
Figure 14. Global Antibody and Recombinant Protein CDMO Market Share by Players in 2022
Figure 15. Global Top Antibody and Recombinant Protein CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Antibody and Recombinant Protein CDMO Revenue in 2022
Figure 17. North America Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
Figure 19. North America Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
Figure 20. North America Antibody and Recombinant Protein CDMO Market Share by Country (2018-2033)
Figure 21. United States Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Antibody and Recombinant Protein CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 24. Europe Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
Figure 25. Europe Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
Figure 26. Europe Antibody and Recombinant Protein CDMO Market Share by Country (2018-2033)
Figure 27. Germany Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. France Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. U.K. Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Italy Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Russia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Nordic Countries Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. China Antibody and Recombinant Protein CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 34. China Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
Figure 35. China Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
Figure 36. Asia Antibody and Recombinant Protein CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 37. Asia Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
Figure 38. Asia Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
Figure 39. Asia Antibody and Recombinant Protein CDMO Market Share by Region (2018-2033)
Figure 40. Japan Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. South Korea Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. China Taiwan Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Southeast Asia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. India Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Australia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Type (2018-2033)
Figure 48. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Application (2018-2033)
Figure 49. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Country (2018-2033)
Figure 50. Brazil Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 51. Mexico Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. Turkey Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Saudi Arabia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Israel Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. GCC Countries Antibody and Recombinant Protein CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Batavia Biosciences Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 57. Grifols Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 58. Cerbios-Pharma SA Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 59. HALIX Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 60. Biovian Oy Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 61. Catalent Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 62. Goodwin Biotechnology Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 63. Merck Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 64. Hangzhou Hs-biopharm Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 65. Wuxibiologics Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 66. Bioinnobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 67. Thousand Oaks Biopharmaceuticals Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 68. Eurogentec Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 69. HJB Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 70. Bibo Pharma Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 71. MabPlex International Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 72. Genscriptprobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 73. Vetter Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 74. Etinpro (Beijing) Co Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 75. Boehringer Ingelheim BioXcellence Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 76. Lonza Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 77. 3SBio Inc Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 78. Porton Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2018-2023)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed